Element card for assessment element G0011 in HTA Core Model Application for Pharmaceuticals (2.0) application

G. Organisational aspects


How are the other interest groups taken into account in the planning / implementation of the technology?

Not core

It may be useful to know who are the possible stakeholders, as well as what kind of co-operation exists and what kind of interaction is needed. The stakeholders could be e.g. the pharmaceutical industry and companies offering technologies for screening, authorities (national / regional), registry, administrative parties, municipalities, policy makers / decision makers, staff groups, GPs/primary care physicians and patient organisation. One can also ask: Has the patient organisation taken part into the evaluation process? Has it been involved from the beginning (in the planning) or in the later stages for example as commentator?

Literature search, reports and documents of hospitals, own study: questionnaires and interviews of different actors of the screening process (monitoring authorities, hospitals, hospital districts, screening units, laboratory, manufacturers, registry, participants).


A0022, B0015, F0003, F0011,

{1, 14, 27}